利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.031 秒)

    PREVENTIVE/REMEDY FOR ARTERIOSCLEROSIS
    1.
    发明申请
    PREVENTIVE/REMEDY FOR ARTERIOSCLEROSIS 审中-公开
    预防/治疗前列腺增生症

    公开(公告)号：US20090239938A1

    公开(公告)日：2009-09-24

    申请号：US12173244

    申请日：2008-07-15

    申请人： Takashi KADOWAKI ,  Toshimasa YAMAUCHI ,  Naoto KUBOTA ,  Yasuo TERAUCHI ,  Tetsuya KUBOTA ,  Tetsuo NODA ,  Ryozo NAGAI ,  Yasushi IMAI

    发明人： Takashi KADOWAKI ,  Toshimasa YAMAUCHI ,  Naoto KUBOTA ,  Yasuo TERAUCHI ,  Tetsuya KUBOTA ,  Tetsuo NODA ,  Ryozo NAGAI ,  Yasushi IMAI

    IPC分类号： A61K31/7088

    CPC分类号： A61K38/2264 ,  A61K48/00

    摘要： A scavenger receptor A expression down-regulator and a drug for preventing or treating arteriosclerosis which contain, as the active ingredient, a C-terminal globular domain of adiponectin, adiponectin, or a gene encoding the domain or adiponectin.According to the present invention, there is provided a preventive or therapeutic agent capable of directly preventing intimal thickening, which constitutes an essential feature of arteriosclerosis. This effect can be attained through arresting the onset and development of arteriosclerosis by reducing the expression level of scavenger receptor A in arterial walls and preventing lipid buildup in macrophages.

    摘要翻译： 清道夫受体A表达下调和用于预防或治疗动脉硬化的药物，其含有脂联素，脂联素或编码结构域或脂联素的基因的C-末端球状结构域作为活性成分。 根据本发明，提供能够直接防止内膜增厚的预防或治疗剂，其构成动脉硬化的基本特征。 通过降低动脉壁中清道夫受体A的表达水平并防止巨噬细胞中的脂质积聚，可以通过阻止动脉硬化的发生和发展来实现该效果。

    ADIPONECTIN RECEPTOR AND GENE ENCODING THE SAME
    3.
    发明申请
    ADIPONECTIN RECEPTOR AND GENE ENCODING THE SAME 有权
    ADIPONECTIN受体和编码其的基因

    公开(公告)号：US20120027760A1

    公开(公告)日：2012-02-02

    申请号：US13153017

    申请日：2011-06-03

    申请人： Takashi KADOWAKI ,  Toshimasa Yamauchi ,  Ryozo Nagai ,  Junji Kamon

    发明人： Takashi KADOWAKI ,  Toshimasa Yamauchi ,  Ryozo Nagai ,  Junji Kamon

    IPC分类号： C07K16/18 ,  A61K39/395 ,  C12N5/12

    CPC分类号： C07K14/72 ,  Y10S435/81

    摘要： The object is to isolate and identify human and mouse adiponectin receptors, to provide a novel protein having adiponectin binding ability, and to provide a screening method and screening kit for a ligand, agonist and antagonist to an adiponectin receptor using such protein. To achieve this object, a protein is used, as novel protein having adiponectin binding ability, that is (a) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8, or (b) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8 with one or more amino acids deleted, replaced or added, and having adiponectin binding ability.

    摘要翻译： 目的是分离和鉴定人和小鼠脂联素受体，以提供具有脂联素结合能力的新型蛋白质，并提供使用这种蛋白质的脂联素受体的配体，激动剂和拮抗剂的筛选方法和筛选试剂盒。 为了实现这个目的，使用蛋白质作为具有脂联素结合能力的新型蛋白质，即（a）包含根据Seq的氨基酸序列的蛋白质。 No.2,4,6或8，或（b）包含根据Seq的氨基酸序列的蛋白质。 具有一个或多个缺失，替换或添加的氨基酸并具有脂联素结合能力的2,4,6或8号。

    ADIPONECTIN EXPRESSION-INDUCING AGENTS AND USES THEREOF
    4.
    发明申请
    ADIPONECTIN EXPRESSION-INDUCING AGENTS AND USES THEREOF 审中-公开
    ADIPONECTIN表达诱导剂及其用途

    公开(公告)号：US20100273708A1

    公开(公告)日：2010-10-28

    申请号：US12762437

    申请日：2010-04-19

    申请人： Takashi KADOWAKI ,  Toshimasa Yamauchi ,  Shoko Kitajima ,  Yusuke Ito

    发明人： Takashi KADOWAKI ,  Toshimasa Yamauchi ,  Shoko Kitajima ,  Yusuke Ito

    IPC分类号： A61K38/17 ,  A61P3/00

    CPC分类号： C07K14/47 ,  A61K38/00 ,  A61K48/00 ,  G01N33/6875 ,  G01N33/74 ,  G01N33/92 ,  G01N2500/10 ,  G01N2800/044

    摘要： The present invention provides adiponectin expression-inducing agents, and therapeutic agents using the same for obesity and obesity-related diseases such as cardiovascular diseases or metabolic diseases, as well as methods of searching for adiponectin expression-inducing agents. KLF9, which can bind to the 32-bp fragment of position −188 to position −157 from the adiponectin expression start site, was demonstrated to enhance adiponectin promoter activity. Therefore, the present invention uses KLF9 as an adiponectin expression-inducing agent, and suggests that KLF9 replenishment therapy is useful for preventing and/or treating obesity or obesity-related diseases including metabolic diseases such as insulin resistance and type II diabetes, and cardiovascular diseases.

    摘要翻译： 本发明提供了脂联素表达诱导剂和使用其的治疗剂用于肥胖症和肥胖相关疾病如心血管疾病或代谢疾病，以及搜索脂联素表达诱导剂的方法。 KLF9可以结合位点-188的32-bp片段，从脂联素表达起始位点到位置-157，证明增强脂连蛋白启动子活性。 因此，本发明使用KLF9作为脂联素表达诱导剂，并且表明KLF9补充疗法可用于预防和/或治疗肥胖症或肥胖相关疾病，包括诸如胰岛素抵抗和II型糖尿病等代谢疾病和心血管疾病 。